Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
UCBCares: Providing Dedicated Patient Support
Clinical studies at UCB: How are medicines made and tested?
Twitter Feed
-
The drug development process can take 10-15 years from early-stage discovery to marketing authorization. #AI has the potential to accelerate this process and make it significantly more efficient. Find out more https://t.co/QSHqRHanoZ https://t.co/Bt4XHvcq
— UCB News (@ucb_news) 24.01.2020 -
#DYK that women who experience a first fragility fracture are at significant risk for experiencing subsequent fractures, particularly in the 2 years after the fracture? Read a summary of the findings published in the Journal of Bone and Mineral Research h
— UCB News (@ucb_news) 22.01.2020 -
Based on a recent UCB survey, almost 1 in 5 patients living with #osteoporosis reported having to reduce their working hours, and one in 8 said the condition meant they had to give up work completely. https://t.co/PB9HKY1KXm https://t.co/sCYjE5yE5O
— UCB News (@ucb_news) 10.01.2020
Instagram Feed
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
